From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Beyond HER2-Low: Understanding the Emerging HER2–Ultra Low Classification

View all
FROM THE EDITORS

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

 

 

Katie Newlin, RN, MSN, AGPCNP-BC

Washington University in St. Louis/Siteman Cancer Center

 

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Resources

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

News & Literature Highlights

Journal of Surgical Oncology

Do racial and income disparities exist in the application of 21-gene recurrence score?

JAMA Oncology

Vaginal estrogen therapy use and survival in females with breast cancer

Journal of Clinical Oncology

Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial

Cancers

CDK4/6 inhibitors plus endocrine therapy in early-stage HR+/HER2- breast cancer: Updated meta-analysis of phase III trials

American Medical Journal

Updates in advanced hormone receptor-positive breast cancer: From circulating tumor DNA-guided therapy to precision medicine

Journal of Clinical Oncology

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study

Science Progress

Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence

Journal of Clinical Oncology

Single center study of efficacy and safety of capivasertib in hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC)

Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Advertisement
Case Studies

Navigating Treatment Adherence in Early-Stage Breast Cancer

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

Advertisement
Quizzes
Test your knowledge of treatment adherence in early-stage breast cancer
Test your knowledge of isolated brain metastasis in BRCA2-mutated HR+ HER2- breast cancer
Test your knowledge of genetic testing and risk intervention based on family history of early-onset breast cancer